Andrew Rawdin
BSc (91Ö±²¥ Hallam), MRes (York)
Population Health, School of Medicine and Population Health
Health Economic Modeller
a.rawdin@sheffield.ac.uk
+44 114 222 0823
+44 114 222 0823
Regent Court (ScHARR)
Full contact details
Andrew Rawdin
Population Health, School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
91Ö±²¥
S1 4DA
Population Health, School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
91Ö±²¥
S1 4DA
- Profile
-
I joined ScHARR in 2006 after gaining a BSc in Mathematics at 91Ö±²¥ Hallam University and an MRes in Mathematics and Ecology at the University of York.
- Research interests
-
My research interests are:
- Discrete event simulation modelling
- Health economic modelling
- Development of a formal framework for the validation of computer simulation models in health economics
- Economic modelling of Public Health interventions
- Population dynamics modelling in epidemic disease transmission
- Investigation of relationships between long term degenerative diseases and exposure to industrial pollutants.
I am currently working on the following projects:
- Economic effectiveness of pharmaceutical interventions for hepatocellular carcinoma
- The comparative economics effectiveness of different treatment methodologies for renal failure
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- . BMC Psychiatry, 15.
- . PharmacoEconomics, 33(8), 833-847.
- . BMC Psychiatry, 15(1).
- . Public Health, 128(9), 804-810.
- . Value in Health, 13(2), 215-221.
- . Health technology assessment (Winchester, England), 13(2).
- . Health Technology Assessment, 16(20).
- . Health Technology Assessment, 14(25).
- . Health Technology Assessment, 18(17).
- . Health Technology Assessment, 18(16).
All publications
Journal articles
- . npj Digital Medicine, 4.
- . Frontiers in Public Health, 8.
- . Health Technology Assessment, 24(29).
- . Applied Health Economics and Health Policy, 17(3), 295-313.
- . PharmacoEconomics.
- . PharmacoEconomics, 36(7), 759-768.
- . PharmacoEconomics, 36(8), 903-915.
- . Health Technology Assessment, 21(71), 1-258.
- . Journal of Epidemiology and Community Health, 71, 897-904.
- . PharmacoEconomics, 35(8), 805-815.
- . Health Technology Assessment, 20(78), 1-406.
- . BMC Psychiatry, 15.
- . PharmacoEconomics, 33(8), 833-847.
- . BMC Psychiatry, 15(1).
- . Public Health, 128(9), 804-810.
- A review of discrete event simulation in National Coordinating Centre for Health Technology Assessment-funded work and a case study exploring the cost-effectiveness of testing for thrombophilia in patients presenting with an initial idiopathic venous thromboembolism.. J. Simulation, 4, 14-23.
- . Value in Health, 13(2), 215-221.
- . Health technology assessment (Winchester, England), 13(2).
- . Health Technology Assessment, 20(78), 407-424.
- . Health Technology Assessment, 16(20).
- . Health Technology Assessment, 14(25).
- . SN Comprehensive Clinical Medicine.
- . Health Technology Assessment, 19(18), 1-120.
- . Health Technology Assessment, 18(17).
- . Health Technology Assessment, 18(16).
Conference proceedings papers
- . Value in Health, Vol. 17(7) (pp A458-A459)
- Clopidogrel is cost-effective compared with aspirin in United Kingdom patients with a myocardial infarction who subsequently sustain an ischaemic stroke or peripheral arterial disease event. VALUE HEALTH, Vol. 11(3) (pp A194-A195)
Posters
- Assessing the cost of parathyroidectomy as a treatment for uncontrolled secondary hyperparathyroidism in stage 5 chronic kidney disease.
- Cost effectiveness of group art therapy for patients with non-psychotic mental health disorders in England and Wales (2014).
Preprints
- Teaching interests
-
My teaching interests are:
- Supervising MSc dissertation projects
- Professional activities and memberships
-
I am a member of the ScHARR Marketing Committee